SCHEDULE 13G/A: BlackRock Discloses 5.9% Passive Stake in Fulgent Genetics
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.9% beneficial ownership in Fulgent Genetics, Inc. as a passive institutional investor.
Summary
- BlackRock, Inc. has filed Amendment No. 3 to its Schedule 13G regarding its beneficial ownership in Fulgent Genetics, Inc.
- As of March 31, 2025, BlackRock beneficially owns 1,819,823 shares of Fulgent Genetics' common stock.
- This ownership represents 5.9% of the class of securities.
- BlackRock holds sole voting power over 1,783,630 shares and sole dispositive power over all 1,819,823 shares.
- The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Fulgent Genetics.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment as it does not report on company performance or strategic changes, but rather a passive investment stake.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a large institutional asset manager, BlackRock, indicating its passive investment stake in Fulgent Genetics, a company operating in the genetic testing and diagnostics industry. Such disclosures are common for major asset managers holding significant, but non-controlling, positions across various public companies.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution for the new Power of Attorney by BlackRock, Inc. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 04/03/2025 | Date of signature for the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Fulgent Genetics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment, Ownership Disclosure, Genetic Testing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.